Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Geert A. Huls is active.

Publication


Featured researches published by Geert A. Huls.


Leukemia | 2016

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012

Avinash G. Dinmohamed; Otto Visser; Y van Norden; N.M.A. Blijlevens; J.J. Cornelissen; Geert A. Huls; Peter C. Huijgens; Pieter Sonneveld; A.A. van de Loosdrecht; G.J. Ossenkoppele; B. Lowenberg; Mojca Jongen-Lavrencic

Large, comprehensive population-based studies in acute myeloid leukemia (AML) are scarce. We conducted a nationwide population-based study on treatment, trial participation and survival among all adult patients diagnosed with AML (n=12 032) and acute promyelocytic leukemia (APL; n=585) in the Netherlands between 1989–2012. Patients were categorized into four periods and four age groups (18–40, 41–60, 61–70 and >70 years). The application of allogeneic stem cell transplantation increased over time among AML patients up to age 70 years. For APL patients, the use of chemotherapy increased across all age groups. When a clinical trial was open for accrual in the Netherlands, the inclusion rates were 68%, 57%, 30% and 12% for AML patients in the four age groups, respectively (data for APL unavailable). Relative survival improved over time among AML (up to age 70 years) and APL patients. In the period 2007–2012, 5-year relative survival rates were 54%, 38%, 14% and 2% for AML patients and 84%, 75%, 54% and 37% for APL patients in the four age groups, respectively. As survival remained poor for older AML patients over the last two decades, clinical trials and active participation in those trials, are warranted that explore innovative treatment strategies for this elderly population.


Blood | 2010

Gene Expression Profiling In Leukemic Stem Cell-Enriched AML CD34(+) Cell Fraction Identifies Target Genes That Predict Prognosis In Normal Karyotype AML

Carolien M. Woolthuis; Hendrik J. M. de Jonge; Annet Z. Vos; André B. Mulder; Eva van den Berg; P. M. Kluin; Karen van der Weide; Evelina S. De Bont; Geert A. Huls; Edo Vellenga; Jan Jacob Schuringa


Blood | 2008

Long-Term Expansion and Self Renewal Is Contained in the CD34+, but Not the CD34-Subfraction of Nucleophosmin Mutated Acute Myeloid Leukemia Cells

Carolien M. Woolthuis; Lina Han; Djoke van Gosliga; Philip M. Kluin; Edo Vellenga; Jan Jacob Schuringa; Geert A. Huls


Blood | 2011

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program

Geert A. Huls; Lieke H. van der Helm; Canan Alhan; P. Wijermans; Marinus van Marwijk Kooy; Martijn R. Schaafsma; Bart J. Biemond; Aart Beeker; Mels Hoogendoorn; Bastiaan P. van Rees; Okke de Weerdt; Jurgen Wegman; Eduard J. Libourel; Sylvia A. Luykx-de Bakker; Monique C. Minnema; Rolf E. Brouwer; Fransien Croon-de Boer; Matthias Eefting; Kon-Siong G. Jie; Arjan A. van der Loosdrecht; Jan Koedam; Nic J. G. M. Veeger; Edo Vellenga


Blood | 2017

Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (≥ 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15)

Geert A. Huls; Dana A. Chitu; Violaine Havelange; Mojca Jongen-Lavrencic; Arjen van de Loosdrecht; Bart J. Biemond; Harm Sinnege; Beata Hodossy; Carlos Graux; Marinus van Marwijk Kooij; Okke de Weerdt; Dimitri A. Breems; Saskia K. Klein; Jürgen Kuball; Gert J. Ossenkoppele; Bob Löwenberg; Edo Vellenga


Nederlands Tijdschrift voor Hematologie | 2013

Het myelodysplastisch syndroom: richtlijnen voor therapie 2013

A.A. van de Loosdrecht; Geert A. Huls; P. Wijermans; B. Lowenberg; Mojca Jongen-Lavrencic; T.J.M. de Witte; J.H. Jansen; G.E. de Greef; P. Muus; M. van Marwijk Kooy; Ron Schaafsma; T. van Maanen; Wendy Deenik; Aart Beeker; Rolf E. Brouwer; Mels Hoogendoorn; H.G.P. Raaijmakers; Dimitri A. Breems; Gregor Verhoef; Hendricus Schouten; P.A. von dem Borne; Jürgen Kuball; Bart J. Biemond; Corien Eeltink; Edo Vellenga; Gj Ossenkoppele


Leukemia Research | 2011

286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine

Canan Alhan; Theresia M. Westers; Corien Eeltink; C. Cali; Geert A. Huls; G.J. Ossenkoppele; A.A. van de Loosdrecht


Nederlands Tijdschrift voor Hematologie | 2014

Het myelodysplastisch syndroom: adviezen voor ijzerchelatie bij secundaire hemochromatose

E.M.P. Cremers; L. de Swart; Geert A. Huls; P. Wijermans; B. Lowenberg; Mojca Jongen-Lavrencic; G.E. de Greef; P. Muus; M. van Marwijk Kooy; Ron Schaafsma; T. van Maanen; Wendy Deenik; Aart Beeker; Rolf E. Brouwer; Mels Hoogendoorn; Dimitri A. Breems; H.G.P. Raaijmakers; Gregor Verhoef; Hendricus Schouten; P.A. von dem Borne; Jürgen Kuball; Bart J. Biemond; Edo Vellenga; Gj Ossenkoppele; T.J.M. de Witte; A.A. van de Loosdrecht


Archive | 2013

Het myelodysplastisc h syndroom: richtlijnen voor diagnostiek 2013 Myelodysplastic syndromes: guidelines for diagnosis 2013

Geert A. Huls; P. Wijermans; B. Lowenberg; Mojca Jongen-Lavrencic; T.J.M. de Witte; J.H. Jansen; P. Muus; M. van Marwijk Kooy; Ron Schaafsma; T. van Maanen; Wendy Deenik; Aart Beeker; Mels Hoogendoorn; Jürgen Kuball; Edo Vellenga


Nederlands Tijdschrift voor Hematologie | 2013

Het myelodysplastisch syndroom: richtlijnen voor diagnostiek 2013

A.A. van de Loosdrecht; Geert A. Huls; P. Wijermans; B. Lowenberg; Mojca Jongen-Lavrencic; T.J.M. de Witte; J.H. Jansen; Theresia M. Westers; G.E. de Greef; P. Muus; M. van Marwijk-Kooy; Ron Schaafsma; T. van Maanen; Deenik; Aart Beeker; René Brouwer; Mels Hoogendoorn; Dimitri A. Breems; H.G.P. Raaijmakers; G. Verhoef; Hendricus Schouten; P.A. von dem Borne; Jürgen Kuball; E. Biemond; Edo Vellenga; Gj Ossenkoppele

Collaboration


Dive into the Geert A. Huls's collaboration.

Top Co-Authors

Avatar

Edo Vellenga

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mels Hoogendoorn

Medisch Centrum Leeuwarden

View shared research outputs
Top Co-Authors

Avatar

Mojca Jongen-Lavrencic

Erasmus University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

B. Lowenberg

VU University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carolien M. Woolthuis

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge